Can GSK Market Breo Ellipta Dosing Advantage Without Adherence Advantage?

After successful advisory panel – at least for adult asthma indication – Breo Ellipta seems headed for an expanded label, but GSK is still struggling to find some clinical differentiation from its aging twice-daily Advair.